Results from the phase II CABOSUN clinical trial, showing cabozantinib to be superior to sunitinib as first-line treatment for advanced kidney cancer, were presented at the European Society for Medical Oncology (ESMO) congress in Copenhagen this week. Read more
Results from the S-TRAC study were presented at the European Society of Medical Oncology. (ESMO) congress in Copenhagen this week. The results show that sunitinib improved disease-free survival in patients with localised kidney cancer that had been surgically removed; a group considered high-risk for [...]
by Deb Maskens, Kidney Cancer Canada The American Society of Clinical Oncology (ASCO) held its annual Genitourinary (GU) Cancers Symposium in San Francisco from January 7-9. The theme of this year’s Symposium was “Patient-Centric Care: Translating Research to Results”. The [...]
Has Immune Checkpoint blockade re-established immunotherapy as a Key Pillar of Kidney cancer care? A panel led by Dr. Michael Atkins discusses the current state of immuno-oncology for kidney cancer.